Yale Medicine School: Following Yale Investigator-Led Trials, FDA Approves First Drug To Delay Onset Of Type 1 Diabetes
November 19, 2022
November 19, 2022
NEW HAVEN, Connecticut, Nov. 19 (TNSres) -- Yale School of Medicine issued the following news:
On November 17, the FDA approved teplizumab, the first drug with the ability to change the course of type 1 diabetes, or any autoimmune disease. Yale School of Medicine played a crucial role in the drug's trials, most of which were led by Kevan Herold, MD, C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology).
Type 1 diabetes is one of the most common chr . . .
On November 17, the FDA approved teplizumab, the first drug with the ability to change the course of type 1 diabetes, or any autoimmune disease. Yale School of Medicine played a crucial role in the drug's trials, most of which were led by Kevan Herold, MD, C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology).
Type 1 diabetes is one of the most common chr . . .